Xanodyne wins bid for aaiPharma's pharmaceutical arm

Xanodyne Pharmaceuticals has emerged as the winning bidder for aaiPharma's pharmaceutical division. Xanodyne will pay $209 million and buy up to $30 million in services from aaiPharma. "We're extremely pleased that we've reached a favorable conclusion to the auction process," said aaiPharma's president and CEO Ludo Reynders. "This will significantly help the company in rebuilding its financial structure."

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.